Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2004

01-09-2004 | Original Articles

Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome

Authors: L. Michaux, I. Wlodarska, I. Theate, M. Stul, J.-M. Scheiff, V. Deneys, A. Ferrant, A. Hagemeijer

Published in: Annals of Hematology | Issue 9/2004

Login to get access

Abstract

A patient with mantle cell lymphoma (MCL) of the pleomorphic blastoid subtype is reported. The disease was clinically aggressive and refractory to chemotherapy, and the patient survived only 2 months. Cytogenetically, a t(11;19;14)(q13;q13;q32) was found. Fluorescent in situ hybridization (FISH) and molecular analyses demonstrated involvement of the BCL1/CCND1 locus in a three-way translocation. In addition, subclonal abnormalities of the region 8q24 manifested either as a t(8;22)(q24;q11)/CMYC rearrangement or trisomy 8 were identified. The pathogenetic impact of this very uncommon association of BCL1/CCND1 and CMYC rearrangements in MCL is discussed and the literature is reviewed.
Literature
1.
Au WY, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD (2000) 8q24 Translocations in blastic transformation of mantle cell lymphoma. Haematologica 85:1225–1227PubMed
2.
Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R (2001) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98:3082–3086CrossRefPubMed
3.
Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, Garcia JL, Flores T, Gonzalez M, Lopez-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miro R, Campo E (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365–4374PubMed
4.
Bentz M, Plesch A, Bullinger L, Stilgenbauer S, Ott G, Muller-Hermelink HK, Baudis M, Barth TF, Moller P, Lichter P, Dohner H (2000) t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27:285–294PubMed
5.
de Boer CJ, van Krieken JH, Schuuring E, Kluin PM (1997) Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol 8(Suppl 2):109–117
6.
Davis M, Malcolm S, Rabbitts TH (1984) Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature 308:286–288PubMed
7.
Fisher RI (1996) Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 7(Suppl 6):S35–S39PubMed
8.
Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ (2002) Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol 15:1266–1272CrossRefPubMed
9.
Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, Campo E (1999) c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia 13:2087–2093CrossRefPubMed
10.
Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414–3421CrossRefPubMed
11.
ISCN (1995) In: Mitelman F (ed) An international system for human genetic nomenclature. Karger, Basel
12.
Jaffe ES, Harris NL, Diebold J, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC, Lyon, pp 168–170
13.
Lovec H, Grzeschiczek A, Kowalski MB, Moroy T (1994) Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13:3487–3495PubMed
14.
Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA, Dyer MJ, Novo FJ, Calasanz MJ, Siebert R (2002) Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 98:470–474CrossRefPubMed
15.
Michaux L, Dierlamm J, Wlodarska I, Bours V, Van den Berghe H, Hagemeijer A (1997) t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet 94:36–43CrossRefPubMed
16.
17.
M’kacher R, Farace F, Bennaceur-Griscelli A, Violot D, Clausse B, Dossou J, Valent A, Parmentier C, Ribrag V, Bosq J, Carde P, Turhan AG, Bernheim A (2003) Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet 143:32–38CrossRefPubMed
18.
Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T, Edgren H, Ferrer A, Vilpo J, Elonen E, Vettenranta K, Franssila K, Knuutila S (2003) Abnormal expression of apoptosis-related genes in haematological malignancies: over expression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120:434–441CrossRefPubMed
19.
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185–197PubMed
20.
Tirier C, Zhang Y, Plendl H, Weber-Matthiesen K, Langer W, Heit W, Schlegelberger B (1996) Simultaneous presence of t(11;14) and a variant Burkitt’s translocation in the terminal phase of a mantle cell lymphoma. Leukemia 10:346–350PubMed
21.
Vaishampayan UN, Mohamed AN, Dugan MC, Bloom RE, Palutke M (2001) Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy. Br J Haematol 115:66–68CrossRefPubMed
22.
Vizcarra E, Martinez-Climent JA, Benet I, Marugan I, Terol MJ, Prosper F, Marco J, Sanchez D, Ferrandez A, Tormo M, Sarsotti E, Ferrer R, Garcia M, Ortuno F, Montagud M, Garcia-Conde J (2001) Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. Hematol J 2:234–241CrossRefPubMed
23.
de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W, Grogan TM, Said JW, Koeffler HP (2003) Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 12:35–43CrossRefPubMed
24.
Wlodarska I, Pittaluga S, Hagemeijer A, Wolf-Peeters C, Van den Berghe H (1999) Secondary chromosome changes in mantle cell lymphoma. Haematologica 84:594–599PubMed
25.
Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila H, Franssila K, Knuutila S (2002) Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119:905–915CrossRefPubMed
Metadata
Title
Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome
Authors
L. Michaux
I. Wlodarska
I. Theate
M. Stul
J.-M. Scheiff
V. Deneys
A. Ferrant
A. Hagemeijer
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-004-0879-2

Other articles of this Issue 9/2004

Annals of Hematology 9/2004 Go to the issue

Original Article

Distribution of ABO blood groups in acute leukaemias and lymphomas

Original Article

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

Case Report

Aneurysmatic dilatation of ascending aorta in a patient with β-thalassemia and a pseudoxanthoma elasticum-like syndrome

Case Report

Concomitant occurrence of MALT lymphoma and multiple myeloma

Original Article

Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation

Review Article

Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits